Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Veritone Inc — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Veritone Inc trades at $0.53 (market cap $59.95M). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 81.4× Veritone Inc's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Veritone Inc for 13 Days on average.
| TVTX | VERI | |
|---|---|---|
Market Cap | $4.88B | $59.95M |
Volume | 1,668,577 | 2,880,267 |
Sector | Health | Technology |
52-Week High | $67.52 | $8.39 |
52-Week Low | $26.79 | $0.53 |
Typical Hold Time | 0 Days | 13 Days |
Enterprise Value | $5.01B | $95.34M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Veritone (VERI) trades at $0.59, down 2.64% on the day, with a bearish technical signal but oversold RSI readings. The company reported a net loss of $111.73M on $92.19M revenue in 2025, with negative cash flow from operations. Recent news includes a $15M equity offering and partnerships like the ATP Media deal, while facing a securities class action investigation.
The outlook remains challenged by persistent losses and cash burn, though analyst consensus is a Buy with a $3.75 price target. Key risks include execution on cost reductions, competitive pressures in AI, and legal overhangs. Upside hinges on revenue acceleration and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
